Cytokinetics Inc.

San Francisco, CA, United States

Cytokinetics Inc.

San Francisco, CA, United States
SEARCH FILTERS
Time filter
Source Type

Provided are compounds of Formula I:^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), R^(8), R^(9), X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Provided are compounds of Formula I:^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), R^(8), R^(9), X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Patent
Astellas Pharma Inc. and Cytokinetics Inc. | Date: 2017-07-19

The problem to be solved by the present invention is to provide a novel pharmaceutical composition for prevention and/or treatment of urinary incontinence, which differs from conventional drugs. The present invention provides a therapeutic agent for prevention and/or treatment of urinary incontinence having 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1 H-pyrrole-3-carboxamide or a salt thereof, as an active ingredient.


Patent
Cytokinetics Inc. | Date: 2015-04-28

Provided herein are compositions and methods for reducing the decline in vital capacity in a subject by administering to the subject a skeletal muscle troponin activator. Also provided are compositions and methods for reducing respiratory decline in a subject, as measured by slow vital capacity (SVC), by administering to the subject a skeletal muscle troponin activator.


Patent
Cytokinetics Inc. | Date: 2017-03-08

Provided herein are compositions and methods for reducing the decline in vital capacity in a subject by administering to the subject a skeletal muscle troponin activator. Also provided are compositions and methods for reducing respiratory decline in a subject, as measured by slow vital capacity (SVC), by administering to the subject a skeletal muscle troponin activator.


Patent
Cytokinetics Inc. | Date: 2015-04-22

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.


Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R^(2), R^(4), R^(5), R^(6), R^(7), R^(8), R^(9), X, Z^(1), Z^(2), Z^(3), Z^(4 )and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, neuromuscular disease, and other indications.


Patent
Cytokinetics Inc. | Date: 2016-03-04

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), X, Z^(1), Z^(2), Z^(3), Z^(4 )and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising sing a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Patent
Cytokinetics Inc. | Date: 2015-08-27

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Loading Cytokinetics Inc. collaborators
Loading Cytokinetics Inc. collaborators